Obesity, Estrone, and Breast Cancer: A Deadly Link Unveiled
A hidden hormone may hold the key to understanding why obesity increases the risk of deadly breast cancer in post-menopausal women. But here's the twist: it's not the usual suspect. The spotlight is on estrone, a hormone produced in fat tissue, which has been overlooked in the shadow of its more famous counterpart, 17β-oestradiol.
This groundbreaking revelation comes from a recent scientific analysis, shedding light on the complex relationship between obesity and breast cancer. The study suggests that estrone, not 17β-oestradiol, becomes the dominant estrogen after menopause, and it's this shift that may fuel the development of aggressive breast cancer.
The Estrone Enigma
In the intricate world of hormones, estrone and 17β-oestradiol are like two sides of the same coin. Before menopause, 17β-oestradiol takes center stage, produced by the ovaries and regulating inflammation. But post-menopause, estrone steps into the limelight, becoming the primary estrogen in the body.
And here's where it gets controversial: despite their chemical similarities, these hormones behave very differently. Dr. Joyce Slingerland's research reveals that while 17β-oestradiol suppresses inflammation, estrone does the opposite, joining forces with NFκB proteins to trigger widespread inflammation.
Estrone's Role in Cancer Progression
The impact of estrone on cancer progression is profound, especially in obese women. In these individuals, estrone levels in fat and breast tissue can be two to four times higher than normal. This surge ignites a powerful inflammatory response, leading to precancerous changes and the activation of cancer-driving genes.
A 2022 study adds another layer to this complex story, showing that estrone-driven inflammation is linked to epithelial-mesenchymal transition, a process closely associated with cancer metastasis. In obese mice with ER+ breast cancer, estrone accelerated tumor growth and caused rapid cancer spread.
Moreover, estrone's ability to suppress immune responses makes it even more challenging for the body to fight cancer cells.
A New Hope: GLP-1 Drugs
Given the strong connection between estrone, inflammation, and cancer progression, Dr. Slingerland proposes a bold idea: using GLP-1 receptor agonists, popular weight-loss drugs, as a potential treatment approach. These drugs have already revolutionized weight loss, and their ability to induce weight loss could potentially curb estrone's cancer-promoting effects.
While lifestyle changes like diet and exercise have shown some benefits, their long-term impact is uncertain. GLP-1 drugs, on the other hand, offer a promising avenue for further exploration.
This discovery opens up a new frontier in the battle against breast cancer, particularly in obese post-menopausal women. It invites us to reconsider our approach to treatment and raises questions about the role of estrone in cancer development. Could targeting estrone be the key to unlocking better treatment outcomes? The answer may lie in the hands of future clinical trials.
